P
eriprocedural myocardial infarction (PMI) has had changing diagnostic criteria over the last decade. Elevation(s) in post-percutaneous coronary intervention (PCI) blood levels of markers of myocyte necrosis, preferably troponin T or I (TnT or TnI), were sufficient for the diagnosis of PMI using the 2000 and 2007 universal definitions of myocardial infarction (MI), [1] [2] [3] but the 2012 universal MI definition requires features additional to biomarker elevations for the diagnosis. These include ischemic chest pain ≥20 minutes, ischemic ECG changes, and/or abnormal findings on either invasive or noninvasive imaging. 4 Given that chest pain is very common post-PCI in the absence of cardiac biomarker elevations, it has usually been assumed to be nonischaemic in origin. Conversely, some patients have cardiac biomarker elevations, but do not have either chest pain or observed changes in invasive or noninvasive imaging that would otherwise meet the criteria for the 2012 PMI definition. [5] [6] [7] Recently, the Society for Cardiovascular Angiography and Interventions (SCAI) has developed PMI criteria similar to post-coronary artery bypass graft (CABG) MI criteria with biomarkers elevation ≥109 upper reference limit (URL) for creatine kinase MB (CKMB) and/or ≥709URL for troponin. 8 These PMI definition changes are likely to reduce the frequency of this event. The consequence of changing definitions may alter the prognostic significance of PMI. 9 Also MI, including PMI, is often a component of the primary endpoint of clinical trials, so if PMI is a less-frequent event, then trial costs may increase.
In order to evaluate the impact of using these different criteria to define PMI on event frequency, we examined post-PCI levels of TnT and CKMB and other additional PMI criteria in the 2012 universal MI definition. The influence of PMI definition on late outcomes after PCI was also studied.
Methods Study Population
All patients undergoing PCI at the cardiac catheterization laboratories of Liverpool Hospital (Sydney, Australia) have clinical, angiographic, and procedural data recorded prospectively in cardiology and laboratory databases. 10 These data include procedural indications, patient demographics, medications, angiographic and lesion characteristics, and stent types (drug-eluting stent [DES] or bare-metal stent). The current study includes patients undergoing PCI for stable coronary heart disease (CHD), unstable angina, and non-STsegment elevation MI (NSTEMI) from October 1, 2003 to September 2010, who had qualifying cardiac biomarkers measurements before and after PCI. These included normal preprocedural TnT levels, or when pre-PCI TnT levels were elevated, and 2 stable or falling levels 6 hours apart. Exclusion criteria included ST-segment elevation myocardial infarction (STEMI), missing pre-and/or post-PCI TnT results, post-PCI TnT and/or CKMB measurements >48 hours, or elevated pre-PCI TnT levels within 72 hours that were not stabilized or falling (Figure 1 ). Post-PCI outcomes are rou- 
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Post-PCI TnT Figure 1 . Study population. The diagram shows the patients from the total angioplasty cohort. Also, the reasons for exclusion from the current study for those who underwent PCI in the study period are shown. *Fifty-two patients had post-PCI TnT >59URL. CHD indicates coronary heart disease; MI, myocardial infarction; NSTEACS, non-ST-segment elevation acute coronary syndrome; PCI, percutaneous coronary intervention; PMI, periprocedural myocardial infarction; SCAI, Society for Cardiovascular Angiography and Interventions; STEMI, ST-segment elevation myocardial infarction; TnT, troponin T; URL, upper reference limit.
tinely assessed for quality assurance (project QA2008/034, approved by the Liverpool Hospital Ethics Committee).
PCI Procedures
Procedural details were as previously described. 10 Stent deployment was performed according to our institutions' DES selective use criteria, 11, 12 and angiographic successful procedures were defined as final post-PCI minimum stenosis diameter reduction to <20% in cases after stenting or to <50% after balloon angioplasty in the presence of grade 3 Thrombolysis In Myocardial Infarction (TIMI) flow. 15 ACC/American Heart Association (AHA) class B2
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and C lesions, calcified lesion, dissection, rotablation, pre-PCI stenosis, culprit lesion length ≥20 mm, deployment of more than 1 stent, maximum deployment pressure duration, and TIMI 3 flow grade post-PCI applied. Odds ratio (OR) and 95% confidence interval (CI) were reported. Hazard ratios (HRs) with 95% CI were performed with Cox's regression analysis of the following events-death, MI, TVR, and ST-which represented MACEs and combined death or MI and at 30 days, 1 year, and 2 years in patients with, and without, PMI according to 2007 and 2012 universal MI definitions and the SCAI definition, respectively. Also, HRs for death and/or MI at 2 years were adjusted for age, pre-PCI TnT level, and eGFR >30 to <60 mL/min per 1.73 m 2 . Five patients whose PCIs were unsuccessful as a result of failure to open chronic total occlusions, and 47 patients who were lost to follow-up, were excluded from Cox's regression analysis of late clinical outcomes. Kaplan-Meier's curves for late outcomes were compared using log-rank testing. P values <0.05 were considered statistically significant.
Results
Patients Clinical and Procedural Characteristics
This study included 742 patients who underwent PCI, 132 for stable CHD and 610 patients for acute coronary syndrome (315 NSTEMI and 295 unstable angina; Table 2 ). The mean age was 64AE11 years, 74% were males, 28% had diabetes, and 60% had ACC/AHA class B2 and C lesions. Periprocedural GPIIb/IIIa inhibitors were used in 20% of PCIs, and in 97% of PCIs, at least 1 stent was deployed (32% had ≥1 DES); 4 patients had rotational atherectomy.
Patients with PMI, compared to those without, were more likely to have HTN, had more renal dysfunction (eGFR 30 to <60 mL/min per 1.73 m 2 ), had longer procedural time, and had ACC/AHA class B2 and C lesions. Demographic and angiographic characteristics of patients with, and without PMI, according to the 2007 and the 2012 universal definitions of MI and the SCAI definition, are shown in Tables 2 and 3 . Pre-PCI TnT levels were <URL in 492 (66%) and were elevated in 250 (34%) patients. PMI using the 2007 universal MI definition occurred in 172 (23%) patients (87 had post-PCI TnT levels elevations >39URL, and 85 had >20% elevation post-PCI TnT levels), whereas PMI, based on the 2012 universal MI definition, occurred only in 99 (13%) patients (44 had post-PCI TnT-level elevations >59URL and 55 with elevated pre-PCI TnT had >20% increase post-PCI levels). The most common additional criteria for the 2012 universal PMI definition was side-branch occlusion in 53 patients (54%); side-branch diameters were ≤1 mm in 48 patients, >1 to <2 mm in 3, and ≥2 mm in 2. Other reasons included persistent or transient slow or no-reflow in 33% and 21% had distal embolization, whereas only 11% patients had ischemic chest pain and 12% had ischemic ECG changes; some had >1 criteria (Figure 2 ). An additional 38 patients met the TnT elevation criteria for the 2012 universal MI definition of PMI without an additional feature (8 patients with normal pre-PCI TnT levels and 30 with elevated pre-PCI TnT levels). According to the SCAI definition, PMI occurred in 19 (2.6%) patients (11 with normal pre-PCI TnT and 8 with elevated pre-PCI TnT levels; 3-way frequency comparison, P<0.001). 165 (29) 85 (49) 195 (30) 55 (56) 242 (33) 8 (42) eGFR 30 to
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23 (3) 5 ( , when pre-PCI TnT level >URL, 10 we found the PMI frequency based on biomarker levels of ≥109URL for CKMB, which equates to TnT levels of ≥179URL in females and ≥339URL in males, occurred in 32 (4.3%) patients. Independent predictors for PMI, based on the 2007 universal MI definition, on the multivariable logistic regression analysis model were coronary dissection, pre-PCI (TnT) >URL, age, and coronary artery stenosis (%) pre-PCI. Applying the 2012 universal MI definition and using the same model identified ACC/AHA class B2 and C lesions and deployment of ≥1 stent as additional independent predictive factors. However, using the same model for the SCAI definition of PMI, the independent predictors were only coronary dissection and renal dysfunction (eGFR, >30 to <60 mL/min per 1.73 m 2 ; Table 4 ).
Clinical Outcomes
Late outcomes of death-recurrent MI, TVR, and MACEwere assessed at a median of 37 (interquartile range, 20 to 55) months post-PCI and were not significantly different in patients with and without PMI, based on the 2007 universal MI definition ( Figure 3 and Table 5 ). Though according to the 2012 universal definition of MI, there was a trend toward worse outcomes in patients with PMI, compared to patients without PMI (death/MI at 2 years; P=0.059). However, the SCAI definition showed an increased frequency of death/MI at 2 years in patients with PMI, compared to those without (P=0.015; Figure 3 ). Kaplan-Meier's analysis for death, MI, and the combination in patients with or without PMI, according to the 2007 and the 2012 universal MI definitions and the SCAI definition, are shown in Figure 4 . The late events of death and/or nonfatal MI were more frequent in patients with normal pre-PCI TnT, but not in patients with elevated pre-PCI TnT levels, according to the 3 definitions of PMI (Table 6 ). 
Discussion
In this study, we report that the frequency of PMI was %60% lower using the 2012, compared to the 2007, universal MI definition and even lower using the SCAI definition. Based on the late outcome data, it appears that PMIs, which were identified using the 2007 universal definition of MI but did not qualify using the 2012 definition or SCAI definition, did not influence the rates of late death or MI. Whereas the universal definitions of PMI are not focused on prognosis, the SCAI definition has been based on post-CABG prognosis. The diagnosis of PMI using the 2012 universal MI definition requires post-PCI TnT-level elevation to >59URL, which corresponds to %39URL for CKMB (mass). Using cardiac magnetic resonance (CMR) imaging, the threshold for detection is ≥39URL for CKMB (mass), which has previously been reported to be prognostic. 16, 17 However, the SCAI definition requires post-PCI TnT-level elevation to ≥709URL or CKMB ≥109URL.
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Defining PMI, with respect of the amount of myonecrosis, has been traditionally based on CKMB (mass) levels. The equivalent extent of myonecrosis, in terms elevations in troponin levels, requires definition of which troponin assay T or I is used and, in particular, if a "conventional" or high sensitivity assay was performed. Additionally, in the case of TnI, detail of the assay manufacturer are also required. A recent study showed that post-PCI troponin (various site assays) elevations to >609URL predicts similar risk of death to >39URL for CKMB, 18 whereas we report here a lessmarked ratio between CKMB and TnT, perhaps reflecting use of the TnT assay. The relationship between TnT levels using the fourth-generation Roche assay and the new "high-sensitivity" TnT assay is not linear at levels <59URL, though these assays tend to correlate very highly at TnT levels >109URL, that is, %>140 ng/mL (0.14 lg/L) using highsensitivity TnT. The SCAI definition sets similar biomarker criteria for PMI, whether post-PCI or post-CABG, whereas the mortality and the morbidity associated with these 2 proce- dures are different. Recently, the group from the Mayo Clinic have reported an adverse prognostic association with post-PCI TnT elevations to >0.25ng/L (259 URL), when the pre-PCI TnT levels are normal. 19 We have also shown that marked TnT elevations post-PCI, when the baseline levels were normal, are associated with increased late death/MI occurrences, though number of events were small. Our findings are similar to those of others, 18 in not finding such an association when pre-PCI TnT levels were elevated. Further it seems plausible, though as yet unproven, that the prognostic importance of TnT elevations may vary with the degree of left ventricular dysfunction and/or haemodynamic instability. It is uncertain as to whether prognostic, rather than diagnostic, criteria for PMI will prevail. 20 We found that the majority of the PMIs using the 2012 definition, which required imaging, were the result of small side-branch occlusions, as previously reported. 21 These were apparently unappreciated by the interventionalist performing the PCI. In routine clinical practice, these are not routinely reported given that the vessels were generally ≤1 mm in diameter and were only identified by careful review comparing the pre-and post-PCI angiography. Nevertheless, the ensuing MIs are of a similar size in term of biomarker elevation to those previously reported on CMR and reported to be prognostic in an earlier era. 22, 23 Whereas PMI has an attributable risk for late mortality, 9,10,24-26 almost all the side-branch occlusions identified were in vessels ≤1 mm, which were too small for side-branch protection and/or intervention techniques. Further study is required to determine whether any strategies were feasible to reduce the frequency of these events, which has been previously reported to be an independent risk for late outcomes. 27 Our study has some limitations. First, it is a single-center study of PCI data collection, which limited study power, especially with respect to mortality. Second, these data were analyzed retrospectively and represent a subgroup of patients -those who had qualifying cardiac biomarkers measured. Operator-requested biomarker assays may be more frequent in instances with clinical symptoms and complicated procedures that may have resulted in a degree of selection bias, leading to our relatively high reported incidence of PMI. Also, high-sensitivity TnT assays only became available in June 2011. The duration of chest pain and slow flow/no-reflow were not recorded, so we cannot specify how transient/ persistent the reduced flow was. Pre-PCI, in this CHD population, there was incomplete database recording of left ventricular (LV) function, and the failure to include an LV function parameter in multivariable analysis is a limitation- though, in this population, this factor is likely to be less important prognostically over 2-year follow-up than in a post-STEMI cohort.
In conclusion, the 2012 universal definition of MI has reduced the frequency of PMI by %60%, compared with the 2007 universal MI definition. However, this reduction in PMI rate seems to be mainly the result of exclusions of events that were not prognostically significant. Furthermore, the main additional factor in the 2012 universal MI definition accounting for these PMI events was small side-branch occlusion. The SCAI definition of PMI resulted in much fewer events, which were associated with a significantly increased rate of late adverse outcomes. Whether this PMI definition or the SCAI definition will achieve widespread acceptance awaits large, prospective studies.
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